ECR Pharmaceuticals Co. has shipped Zolpimist Oral Spray, a prescription sleep aid.


ECR Pharmaceuticals, Zolpimist Oral Spray, sleep aid, sleeping aid, prescription sleep aid, zolpidem tartrate, Hi-Tech Pharmacal, David Seltzer, Steven Ratoff, Novadel Pharma, sleep aid products
































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

ECR Pharmaceuticals releases Zolpimist oral spray

February 4th, 2011

AMITYVILLE, N.Y. – ECR Pharmaceuticals Co. has shipped Zolpimist Oral Spray, a prescription sleep aid.

The Hi-Tech Pharmacal Co. subsidiary said Friday that Zolpimist Oral Spray brings a novel delivery system for zolpidem tartrate, the most widely prescribed sleeping aid in the United States.

Zolpimist Oral Spray unit contains 60 metered sprays and provides the flexibility of administering either a 5-mg or 10-mg dose of the zolpidem active ingredient, according to ECR. As with most prescription hypnotic agents, the spray is federally classified as a CIV controlled substance, the company said.

"Zolpimist is a significant addition to ECR, our branded products subsidiary, and reflects our continuing commitment to build this segment of our business through the marketing of widely used, innovative products," Hi-Tech president and chief executive officer David Seltzer said in a statement.

Steven Ratoff, CEO of Novadel Pharma Inc., the developer of Zolpimist Oral Spray, commented, "We are pleased to have Zolpimist available in the U.S. marketplace."

More than 79 million prescriptions for sleep aid products are written annually in the United States, ECR reported.

Advertisement